|
|
.
See Category: Factors influencing health status and contact with health services
See Header: Genetic susceptibility to malignant neoplasm
ICD-10 (CM) Code and Descriptor
|
Z15.03 |
Genetic susceptibility to malignant neoplasm of prostate
Diagnosis Valid for Male Patient Only
This code is considered unacceptable as a principal diagnosis.
|
Z1503 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 2.31%
|
9.40%
|
15.68%
|
13.63%
|
12.82%
|
10.04%
|
8.50%
|
7.01%
|
5.98%
|
5.94%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z15.03*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
30
|
30
|
|
84153
|
ASSAY OF PSA TOTAL |
23
|
23
|
|
G0103
|
PSA SCREENING |
12
|
12
|
|
G0277
|
HBOT, FULL BODY CHAMBER, 30M |
9
|
33
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
8
|
8
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
8
|
8
|
|
80053
|
COMPREHEN METABOLIC PANEL |
8
|
8
|
|
84154
|
ASSAY OF PSA FREE |
7
|
7
|
|
80061
|
LIPID PANEL |
6
|
6
|
|
81001
|
URINALYSIS AUTO W/SCOPE |
4
|
4
|
|
Q3014
|
TELEHEALTH FACILITY FEE |
4
|
4
|
|
80048
|
METABOLIC PANEL TOTAL CA |
4
|
4
|
|
86316
|
IMMUNOASSAY TUMOR OTHER |
4
|
4
|
|
82565
|
ASSAY OF CREATININE |
3
|
3
|
|
78306
|
BONE IMAGING WHOLE BODY |
3
|
3
|
|
A9503
|
TC99M MEDRONATE |
3
|
3
|
|
72197
|
MRI PELVIS W/O & W/DYE |
3
|
3
|
|
84443
|
ASSAY THYROID STIM HORMONE |
3
|
3
|
|
82043
|
UR ALBUMIN QUANTITATIVE |
3
|
3
|
|
82570
|
ASSAY OF URINE CREATININE |
3
|
3
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z15.03 related to the following DRG Codes:
951
|
